ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/IL-6
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/IL-6
9
trial(s) found.
NCT07589634
Haem
Phase 2
Recruiting
79635322MMY2002: Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma (
TRI-Pro
)
anti-IL-6 monoclonal antibody
placebo
trispecific T-cell engager,BCMA/GPRC5D-targeting
Multiple myeloma
NSW
2139 - Concord - Concord Repatriation General Hospital
NCT05927571
Haem
Phase 1
Recruiting
An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Patients With Relapsed or Refractory Multiple Myeloma (
GO43979
)
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,FcRH5-targeting
+ anti-IL-6 monoclonal antibody
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3181 - Prahran - The Alfred Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NA
NA
NCT05583617
Haem
Phase 1 / Phase 2
Recruiting
A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients With Multiple Myeloma (
PLYCOM
)
CELMoD agent
Cevostamab
Dexamethasone
Iberdomide
Lenalidomide
Tocilizumab
anti-IL-6 monoclonal antibody
bispecific T-cell engager,FcRH5-targeting
cancer therapy
cancer therapy,FcRH5-targeting
cancer therapy,IL-6-targeting
cancer therapy,cereblon-targeting
cereblon modulator
glucocorticoid
immuno-oncology therapy,FcRH5-targeting
immuno-oncology therapy,IL-6-targeting
immunomodulatory imide drug
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
+ anti-IL-6 monoclonal antibody
Multiple myeloma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT05533775
Paed
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (
iMATRIX-GLO
)
bispecific T-cell engager,CD20-targeting
+ anti-IL-6 monoclonal antibody
Non-Hodgkin's lymphoma
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05091424
Haem
Phase 1
Recruiting
A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (
BO43243
)
Bcl2 inhibitor
bispecific T-cell engager,CD20-targeting
+ anti-IL-6 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT04910568
Haem
Phase 1
Recruiting
An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (
CAMMA-1
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,FcRH5-targeting
glucocorticoid
immunomodulatory imide drug
+ anti-IL-6 monoclonal antibody
Multiple myeloma
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3004 - Melbourne, Southbank - Alfred Health
NCT04524871
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (
Morpheus-Liver
)
Amezalpat
Atezolizumab
Bevacizumab
HIF2a inhibitor
Imdatifan
Muzastotug
PPAR-alpha inhibitor
Tiragolumab
Tobemstomig
Tocilizumab
anti-CTLA4 monoclonal antibody
anti-IL-6 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,HIF2a-targeting
cancer therapy,IL-6-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PPAR-alpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ anti-IL-6 monoclonal antibody
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03564340
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16\xD7CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers (
R4018-ONC-1721
)
anti-PD-1 monoclonal antibody
bispecific T-cell engager,MUC16-targeting
+ anti-IL-6 monoclonal antibody
Endometrial cancer
Fallopian tube cancer
Low-grade serous ovarian cancer
Ovarian cancer
Primary peritoneal serous carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT03424005
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (
Morpheus-panBC
)
AKT inhibitor
Abemaciclib
Atezolizumab
Atirmociclib
Bevacizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK4 selective inhibitor
CDK6 inhibitor
Capecitabine
Carboplatin
ER degrader
Eribulin
Fulvestrant
Gemcitabine
Giredestrant
Inavolisib
Ipatasertib
Ladiratuzumab Vedotin
Letrozole
Metformin
Nab-paclitaxel
PI3K alpha inhibitor
Palbociclib
Ribociclib
Sacituzumab Govitecan
Selicrelumab
Tocilizumab
Trastuzumab Deruxtecan
agnostic antibody,CD40-targeting
anti-CD40 agonistic antibody
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-IL-6 monoclonal antibody
anti-LIV1 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
antimetabolite
aromatase inhibitor
biguanide antihyperglycaemic agent
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CD40-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK4 selective-targeting
cancer therapy,CDK6-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,IL-6-targeting
cancer therapy,LIV1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,oestrogen axis-targeting
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CD40-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LIV1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGF-targeting
macrocyclic ketone analogue
oestrogen receptor-targeting therapy
pan-AKT inhibitor
platinum-based antineoplastic agent
selective estrogen receptor degrader
taxane
+ anti-IL-6 monoclonal antibody
Breast cancer
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
WA
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (9)
Recruitment Country and State
VIC (6)
NSW (4)
QLD (2)
WA (2)
SA (1)
NZ (1)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (5)
Phase 2 (1)
Trial Type
Haem (5)
Advanced (3)
Paed (1)
Cancer Therapy Class
IL-6
100%
FcRH5
33%
PD-1/PD-L1
33%
cereblon
22%
CD20
22%
PD-1
22%
PD-L1
22%
VEGF
22%
BCMA
11%
Bcl2
11%
CD38
11%
CTLA4
11%
HIF2a
11%
LAG3
11%
PPAR-alpha
11%
TIGIT
11%
MUC16
11%
AKT
11%
CD40
11%
CDK4
11%
CDK4 selective
11%
CDK6
11%
ERBB2
11%
ER
11%
LIV1
11%
PI3Kalpha
11%
Trop2
11%
oestrogen axis
11%
Facility
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (3)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
2031 - Randwick - Prince of Wales Hospital (2)
2139 - Concord - Concord Repatriation General Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3181 - Prahran - The Alfred Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
NA
4101 - South Brisbane - Queensland Children's Hospital (1)
6009 - Perth - Perth Children's Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Multiple myeloma
Plasma cell disorder
Solid tumour
Lymphoma
Non-Hodgkin's lymphoma
B-cell lymphoma
B-cell malignancy
Chronic lymphocytic leukaemia
Leukaemia
Lymphoid leukaemia
Mature B-cell malignancy
Small lymphocytic lymphoma
Gastrointestinal cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Upper gastrointestinal cancer
Endometrial cancer
Epithelial Ovarian Cancer
Fallopian tube cancer
Gynaecological cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Low-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian cancer
Ovarian serous carcinoma
Peritoneal cancer
Primary peritoneal serous carcinoma
Breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy